Want to see AU:MAP full AI Analyst Report?
MAP Stock Chart & Stats
AU$0.04
<AU$0.01(2.22%)
At close: 4:00 PM EDT
AU$0.04
<AU$0.01(2.22%)
Day’s Range― - ―
52-Week RangeAU$0.04 - AU$0.11
Previous CloseN/A
Volume296.78K
Average Volume (3M)469.77K
Market Cap
AU$41.59M
Enterprise ValueAU$35.84
Total Cash (Recent Filing)AU$11.27M
Total Debt (Recent Filing)AU$3.31M
Price to Earnings (P/E)―
Beta0.99
Next Earnings
Sep 01, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding717,117,250
10 Day Avg. Volume548,444
30 Day Avg. Volume469,774
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)1.17
Price to Sales (P/S)2.43
P/FCF Ratio-2.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.08Price Target Upside112.50% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.01
Revenue Forecast (FY)AU$22.25M
Bulls Say, Bears Say
Bulls Say
Low LeverageA debt-to-equity ratio of 0.10 indicates very low leverage, reducing financial risk and interest burden. This provides durable financial flexibility to fund R&D, lab capacity and collaborations, and to withstand revenue volatility without immediate refinancing pressure.
Positive Free Cash Flow GrowthFree cash flow growth and FCF exceeding net income show the business can generate cash despite accounting losses. Sustained FCF supports operational continuity, selective investment in platform scale, and extends runway for commercialization and partnership activities over the medium term.
Diversified Platform Revenue StreamsA multi-pronged model—clinical/consumer tests, B2B research services, and biotech collaborations—creates multiple durable demand channels. Platform-based sequencing and analytics are reusable assets that enable repeatable services and longer-term partner contracts, strengthening revenue optionality.
Bears Say
Declining Revenue TrendA ~24% revenue decline signals weakening top-line scale, which undermines the economics of lab operations and platform leverage. Persistent top-line contraction risks margin pressure, reduces ability to invest in product development, and can erode partner confidence over several quarters.
Negative Operating Cash FlowContinued negative operating cash flow is a structural issue: it forces reliance on financing or reserves to fund day-to-day operations and growth. Even with positive FCF growth, negative operating cash flow constrains reinvestment in capacity, slows scaling, and heightens liquidity risk over months.
Ongoing Losses And Weak MarginsSustained negative profitability and margins indicate the business has not yet achieved operational leverage. Ongoing losses limit reinvestment, may necessitate future equity or debt raises, and reduce the firm's ability to capture value from partnerships or commercialize therapeutics profitably long-term.
Microba Life Sciences Limited News
MAP FAQ
What was Microba Life Sciences Limited’s price range in the past 12 months?
Microba Life Sciences Limited lowest share price was AU$0.04 and its highest was AU$0.10 in the past 12 months.
What is Microba Life Sciences Limited’s market cap?
Microba Life Sciences Limited’s market cap is AU$41.59M.
When is Microba Life Sciences Limited’s upcoming earnings report date?
Microba Life Sciences Limited’s upcoming earnings report date is Sep 01, 2026 which is in 12 days.
How were Microba Life Sciences Limited’s earnings last quarter?
Microba Life Sciences Limited released its earnings results on Feb 25, 2026. The company reported -AU$0.018 earnings per share for the quarter, missing the consensus estimate of -AU$0.01 by -AU$0.008.
Is Microba Life Sciences Limited overvalued?
According to Wall Street analysts Microba Life Sciences Limited’s price is currently Undervalued.
Does Microba Life Sciences Limited pay dividends?
Microba Life Sciences Limited does not currently pay dividends.
What is Microba Life Sciences Limited’s EPS estimate?
Microba Life Sciences Limited’s EPS estimate is >-0.01.
How many shares outstanding does Microba Life Sciences Limited have?
Microba Life Sciences Limited has 717,117,250 shares outstanding.
What happened to Microba Life Sciences Limited’s price movement after its last earnings report?
Microba Life Sciences Limited reported an EPS of -AU$0.018 in its last earnings report, missing expectations of -AU$0.01. Following the earnings report the stock price went up 1.176%.
Which hedge fund is a major shareholder of Microba Life Sciences Limited?
Currently, no hedge funds are holding shares in AU:MAP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Microba Life Sciences Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$0.08 (112.50% Upside)
AU$0.08 (112.50% Upside)
Blogger Sentiment
Bullish
AU:MAP Sentiment 100%
Sector Average 61%
Sector Average 61%
Insider Transactions
Bought Shares
Worth AU$72.5K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-51.76%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-14.63%
Trailing 12-Months
Company Description
Microba Life Sciences Limited
Microba Life Sciences Limited, established in Brisbane, Australia, in 2017, specializes in providing sophisticated microbiome testing and analytical services. These offerings reach clinicians, individual consumers, and research customers across key international markets, including Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, and the United States. The company delivers pathology, therapeutic, and diagnostic solutions deeply rooted in human gut microbiome science. Central to its operations is a comprehensive Databank, invaluable for unearthing therapeutic leads, fostering consumer health advancements, and identifying crucial diagnostic biomarkers. Moreover, Microba leverages a data-driven therapeutics platform to engineer innovative monoclonal microbial cell therapies aimed at treating inflammatory bowel disease, enhancing cancer immunotherapy, and managing autoimmune disorders.
MAP Stock 12 Month Forecast
Average Price Target
AU$0.08
▲(112.50% Upside)
Technical Analysis
Genetic Technologies
―
BCAL Diagnostics Limited
―
Rhythm Biosciences Ltd.
―
Lumos Diagnostics Holdings Ltd.
―
Genetic Signatures Ltd.
―